Recombinant Human JAM-B/VE-JAM Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human JAM-B/VE-JAM Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support adhesion of J45.01 human acute lymphoblastic leukemia T lymphocytes. Liang, T.W. et al. (2002) J. Immunol. 168:1618.

  When Recombinant Human JAM-B Fc Chimera is immobilized on goat anti-human IgG Fc Chimera antibody coated wells, J45.01 cells (100 µL/well at 10⁶ cells/mL) adhesion is induced in a dose dependent manner after a 2 hour incubation at 37 °C. The ED₅₀ for this effect is 10-60 ng/mL.

• Source: Mouse myeloma cell line, NS0-derived human JAM-B/VE-JAM protein
  

  Human JAM-B (Phe29 - Asn236) Accession # P57087	IEGRMD	Human IgG1 (Pro100 - Lys330)
  N-terminus		C-terminus

• Accession #: P57087
• N-terminal Sequence: Phe29
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: JAM2
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 64-70 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human JAM-B/VE-JAM Fc Chimera Protein, CF

• C21orf43
• CD322 antigen
• CD322
• JAM2
• JAMB
• JAM-B
• JAM-BJAM-IT/VE-JAM
• junctional adhesion molecule 2JAM-2
• junctional adhesion molecule B
• PRO245
• Vascular endothelial junction-associated molecule
• VE-JAM
• VE-JAMVEJAMCD322

Background

The family of juctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial cells or epithelial cells. Some family members are also found on blood leukocytes and platelets. JAM-B, alternatively named vascular endothelial JAM (VE-JAM), is expressed prominently on high endothelial venules of lymphoid organs where it is localized to the intercellular boundaries of high endothelial cells. It is also expressed on the endothelium of a variety of non-lymphoid organs, especially the heart and placenta (3, 5). Human JAM-B cDNA predicts a 298 amino acid residue (aa) precursor protein with a putative 28 aa signal peptide, a 209 aa extracellular region containing two Ig domains, a 23 aa transmembrane domain and a 38 aa cytoplasmic domain containing a PDZ-binding motif and a PKC phosphorylation site. Human JAM-B shares approximately 79% aa sequence homology with its mouse homologue. It also shares approximately 35% aa sequence homology with human JAM-A or JAM-C. JAM-B exhibits homotypic interactions, as well as heterotypic interactions with JAM-C, but not JAM-A (4, 5, 7). It is also a ligand for the integrin alpha ₄ beta ₁. However, the JAM-B/ alpha ₄ beta ₁ interaction is facilitated only after prior adhesion of JAM-B to JAM-C (6). Through its heterotypic interactions with JAM-C, JAM-B is an adhesive ligand for T, NK, and dendritic cells, and may play a role in regulating leukocyte transmigration (5).

The nomenclature used for the JAM family proteins is confusing. VE-JAM has been referred in the literature variously as JAM-B or JAM-3. Until further clarification, R&D Systems has adopted the nomenclature where both mouse and human VE-JAM are referred to as JAM-B.

1. Chavakis, T. et al. (2003) Thromb. Haemost. 89:13.
2. Aurand-Lions, M. et al. (2001) Blood 98:3699.
3. Palmeri, A. et al. (2000) J. Biol. Chem. 275:19139.
4. Cunnigham, S. et al. (2000) J. Biol. Chem. 275:34750.
5. Liang, T. et al. (2002) J. Immunol. 168:1618.
6. Cunningham, A. et al. (2002) J Biol. Chem. 277:27589.
7. Arrate, M. et al. (2001) J. Biol. Chem. 276:45826.

Publications for JAM-B/VE-JAM (1074-VJ)(3)

Publications using 1074-VJ

• Soldati, S;B�r, A;Vladymyrov, M;Glavin, D;McGrath, JL;Gosselet, F;Nishihara, H;Goelz, S;Engelhardt, B; High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4+ T cell arrest on the inflamed BBB under flow in vitro Journal of neuroinflammation 2023-05-23 [PMID: 37221552] (Bioassay, Human)
• PE Day-Walsh, B Keeble, G Pirabagar, SJ Fountain, PA Kroon Transcriptional and Post-Translational Regulation of Junctional Adhesion Molecule-B (JAM-B) in Leukocytes under Inflammatory Stimuli International Journal of Molecular Sciences, 2022-08-03;23(15):. 2022-08-03 [PMID: 35955781] (Western Blot, Mouse)
• Arcangeli M, Bardin F, Frontera V, Bidaut G, Obrados E, Adams R, Chabannon C, Aurrand-Lions M Function of Jam-B/Jam-C interaction in homing and mobilization of human and mouse hematopoietic stem and progenitor cells. Stem Cells, 2014-04-01;32(4):1043-54. 2014-04-01 [PMID: 24357068] (Bioassay, Human)

Bioinformatics

• Gene Symbol: JAM2
• Uniprot:
  • P57087()